PA
AZN icon

Pinnacle Associates’s AstraZeneca AZN Stock Holding History

Pinnacle Associates’s Portfolio AZN Stock Details AZN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$3.71M Buy
18,836
+2,056
+12% +$396K 0.05% 304
2025
Q4 		$3.09M Buy
16,780
+2,223
+15% +$390K 0.04% 324
2025
Q3 		$2.23M Sell
14,557
-260
-2% -$39.4K 0.03% 373
2025
Q2 		$2.07M Sell
14,817
-775
-5% -$109K 0.03% 374
2025
Q1 		$2.29M Buy
15,592
+613
+4% +$88.7K 0.03% 355
2024
Q4 		$1.96M Buy
14,979
+1,856
+14% +$260K 0.03% 369
2024
Q3 		$1.77M Sell
13,123
-2,406
-15% -$388K 0.03% 374
2024
Q2 		$2.42M Buy
15,529
+963
+7% +$145K 0.04% 343
2024
Q1 		$1.97M Buy
14,566
+1,443
+11% +$191K 0.03% 372
2023
Q4 		$1.77M Buy
13,123
+516
+4% +$67.1K 0.03% 379
2023
Q3 		$1.71M Sell
12,607
-95
-0.7% -$13K 0.03% 370
2023
Q2 		$1.82M Buy
12,702
+1,214
+11% +$179K 0.03% 370
2023
Q1 		$1.59M Buy
11,488
+83
+0.7% +$11.2K 0.03% 336
2022
Q4 		$1.55M Sell
11,405
-187
-2% -$23.5K 0.03% 331
2022
Q3 		$1.27M Sell
11,592
-468
-4% -$59.4K 0.03% 354
2022
Q2 		$1.59M Sell
12,060
-1,264
-9% -$166K 0.03% 330
2022
Q1 		$1.77M Buy
13,324
+716
+6% +$85.9K 0.03% 357
2021
Q4 		$1.47M Sell
12,608
-77
-0.6% -$9.06K 0.03% 389
2021
Q3 		$1.52M Buy
12,685
+1,062
+9% +$124K 0.03% 378
2021
Q2 		$1.39M Buy
11,623
+306
+3% +$33.6K 0.03% 383
2021
Q1 		$1.13M Sell
11,317
-4,128
-27% -$415K 0.02% 402
2020
Q4 		$1.54M Buy
15,445
+2,806
+22% +$297K 0.03% 337
2020
Q3 		$1.39M Sell
12,639
-287
-2% -$31.9K 0.03% 325
2020
Q2 		$1.37M Sell
12,926
-6,313
-33% -$652K 0.03% 324
2020
Q1 		$1.72M Buy
19,239
+34
+0.2% +$3.2K 0.05% 270
2019
Q4 		$1.92M Sell
19,205
-75
-0.4% -$7.06K 0.04% 314
2019
Q3 		$1.72M Sell
19,280
-2,044
-10% -$177K 0.04% 323
2019
Q2 		$1.76M Buy
21,324
+7,993
+60% +$627K 0.04% 324
2019
Q1 		$1.08M Buy
13,331
+7,553
+131% +$595K 0.02% 396
2018
Q4 		$439K Buy
5,778
+374
+7% +$29.2K 0.01% 532
2018
Q3 		$428K Buy
5,404
+497
+10% +$37.6K 0.01% 534
2018
Q2 		$345K Sell
4,907
-205
-4% -$14.7K 0.01% 569
2018
Q1 		$357K Sell
5,112
-1,001
-16% -$69.3K 0.01% 550
2017
Q4 		$424K Sell
6,113
-380
-6% -$25.6K 0.01% 520
2017
Q3 		$440K Buy
6,493
+68
+1% +$4.3K 0.01% 512
2017
Q2 		$438K Sell
6,425
-124
-2% -$8.1K 0.01% 516
2017
Q1 		$408K Buy
6,549
+8
+0.1% +$466 0.01% 514
2016
Q4 		$357K Sell
6,541
-400
-6% -$22.7K 0.01% 531
2016
Q3 		$456K Sell
6,941
-1,161
-14% -$75.9K 0.01% 486
2016
Q2 		$489K Buy
8,102
+876
+12% +$50.9K 0.01% 468
2016
Q1 		$407K Sell
7,226
-1,030
-12% -$61.9K 0.01% 488
2015
Q4 		$561K Buy
8,256
+2,333
+39% +$153K 0.01% 445
2015
Q3 		$377K Sell
5,923
-499
-8% -$32.8K 0.01% 488
2015
Q2 		$409K Buy
6,422
+300
+5% +$20.5K 0.01% 495
2015
Q1 		$419K Buy
+6,122
New +$425K 0.01% 486

Other funds holding AZN

IA
Investor AB Stockholm, Sweden $15.1B AUM 29.02% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Legal & General Group
Legal & General Group London, United Kingdom $432B AUM 29.4% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
VAM
Vanguard Asset Management London, Ec4n 8af $117B AUM

Pinnacle Associates's AZN Position: Q1 2026 in Review

Pinnacle Associates increased its AstraZeneca (AZN) stake by 12% in Q1 2026, buying an estimated $396K and bringing the position to 18,836 shares worth $3.71M. The position accounts for 0.05% of the portfolio, ranked #304.

Pinnacle Associates first reported a position in AZN in Q1 2015 and has held it in 45 quarters since. 1,379 funds tracked by Wall St. Rank hold AZN as of Q1 2026.

  • Pinnacle Associates held 18,836 shares of AstraZeneca worth $3.71M as of Q1 2026.
  • Pinnacle Associates bought 2,056 AstraZeneca shares in Q1 2026, an estimated $396K.
  • AstraZeneca made up 0.05% of Pinnacle Associates's portfolio in Q1 2026, its #304 holding.
  • Pinnacle Associates first reported a position in AstraZeneca in Q1 2015 and has held it in 45 quarters since.
  • 1,379 funds tracked by Wall St. Rank held AstraZeneca as of Q1 2026.

Based on Pinnacle Associates's 13F filing for Q1 2026, filed 22 Apr 2026.